Search for content, post, videos

Company in focus: Modus Therapeutics

Swedish drug development company Modus Therapeutics has had a busy year, and 2019 could take them one step closer to having sevuparin on the market. In 2016 the clinical-stage drug development and Karolinska Development portfolio company Dilaforette Holding changed its name to Modus Therapeutics
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.